Related Experiment Video
Updated: Jul 26, 2025
Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
Published on: July 8, 2011
Comparative Evaluation of Lipofectamine and Dendrimer for Transfection of Short RNA Into Human T47D and MCF-10A Cell
Zohreh Jahanafrooz1, Behnaz Bakhshandeh2, Erfan Shirzadi3
1Department of Biology, Faculty of Sciences, University of Maragheh, Maragheh, Iran.
Abstract:
Non-viral transfection approaches are extensively used in cancer therapy. The future of cancer therapy lies on targeted and efficient drug/gene delivery. The aim of this study was to determine the transfection yields of two commercially available transfection reagents (i.e. Lipofectamine 2000, as a cationic lipid and PAMAM G5, as a cationic dendrimer) in two breast cell lines: cancerous cells (T47D) and non-cancerous ones (MCF-10A). We investigated the efficiencies of Lipofectamine 2000 and PAMAM G5 for transfection/delivery of a labeled short RNA into T47D and MCF-10A. In addition to microscopic assessments, the cellular uptakes of the complexes (fluorescein tagged-scrambled RNA with Lipofectamine or PAMAM dendrimer) were quantified by flow cytometry. Furthermore, the safety of the mentioned reagents was assessed by measuring cell necrosis through the cellular PI uptake. Our results showed significantly better efficiencies of Lipofectamine compared to PAMAM dendrimer for short RNA transfection in both cell types. On the other hand, MCF-10A resisted more than T47D to the toxicity of higher concentrations of the transfection reagents. Altogether, our research demonstrated a route for comprehensive epigenetic modification of cancer cells and depicted an approach to efficient drug delivery, which eventually improves both short RNA-based biopharmaceutical industry and non-viral strategies in epigenetic therapy.
Insights
Lipofectamine 2000 showed higher efficiency for short RNA transfection than PAMAM G5 in breast cancer cells. Non-cancerous cells exhibited greater resistance to transfection reagent toxicity.
Area of Science:
- Biotechnology
- Cancer Therapy
- Nanomedicine
Background:
- Non-viral transfection is crucial for targeted cancer therapy.
- Efficient drug and gene delivery systems are key for future cancer treatments.
Purpose of the Study:
- To compare the transfection efficiencies of Lipofectamine 2000 (cationic lipid) and PAMAM G5 (cationic dendrimer).
- To evaluate these reagents in delivering short RNA into cancerous (T47D) and non-cancerous (MCF-10A) breast cell lines.
- To assess the safety and toxicity profiles of the transfection reagents.
Main Methods:
- Investigated transfection efficiency of Lipofectamine 2000 and PAMAM G5 for short RNA delivery.
- Utilized microscopic assessments and flow cytometry to quantify cellular uptake of fluorescein-tagged RNA complexes.
- Assessed reagent safety by measuring cell necrosis via propidium iodide (PI) uptake.
Main Results:
- Lipofectamine 2000 demonstrated significantly higher transfection efficiencies than PAMAM G5 in both T47D and MCF-10A cells.
- MCF-10A cells showed greater resistance to the toxicity of higher concentrations of transfection reagents compared to T47D cells.
Conclusions:
- Lipofectamine 2000 is a more effective reagent for short RNA transfection in breast cell lines.
- This research provides a foundation for epigenetic modification in cancer cells and enhances non-viral drug delivery strategies.
